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PreviewsSince the observation that ST2 is selec-
tively expressed on Th2 cells and not on
Th1 cells (Xu et al., 1998) and that IL-33
preferentially activates Th2 cells (Schmitz
et al., 2005), IL-33 has been closely asso-
ciated with type II immune response.
The report of Kearley et al. (2015) is in
apparent contrast to this paradigm.
Several recent studies also suggest that
IL-33 can activate NK cells (Bourgeois
et al., 2009) to produce the canonical
Th1-like cytokine IFN-g. There is so far
no report of a direct activation of Th1
cells. However, as suggested by Kearley
et al. (2015), IL-33 is probably a pleio-
tropic cytokine whose function extends
beyond the confine of type II response
when combined with other cytokines in
the alternated microenvironment (such
as caused by smoke and infection in the
lung), in the absence of which IL-33 would
induce a type II response by default.
Several earlier reports also show that
IL-33 preferentially induces alternatively
activated macrophage (M2) rather than
classically activated macrophage (M1)
(Kurowska-Stolarska et al., 2009). How-
ever, IL-33 appears to do so indirectly
via the induction of IL-4 and IL-13 pro-
duced by Th2 cells and ILC2s. Kearley
et al. (2015) show that in the absence
of type II cytokines, IL-33 can activate
M1 by upregulating the expression
of ST2 on macrophages. Thus, againthe action of IL-33 on macrophages
is highly dependent on the milieu of
microenvironment.
It should be noted that the pathogen-
esis of COPD is distinct from that of
asthma. COPD is mediated mainly by
the infiltration of inflammatory cells acti-
vated by type I cytokines, whereas
asthma is an allergic response principally
induced by type II cytokines. Thus,
whereas IL-33 can directly elicit an
asthmatic response, smoke-exposure-
induced IL-33, released from the epithe-
lium by concomitant infections, probably
activates a type I response via the differ-
ential modulation of ST2 expression on
ILC2s, macrophages, and NK cells.
The report of Kearley et al. (2015) raises
a number of intriguing questions. What
are the components in the cigarette
smoke that induce elevated expression
of IL-33 in the lung epithelium? What is
the mechanism by which these compo-
nents increase IL-33 expression? How
does smoke exposure differentially regu-
late ST2 expression on ILC2s, macro-
phages, and NK cells? Answers to these
questions would not only provide further
insight into the molecular pathway of
IL-33 function, but also pave the way for
a more effective treatment of the unmet
clinical needs of COPD. Targeting IL-33
by sST2 and anti-IL-33 antibody merits
investigation in clinical COPD.Immunity 4REFERENCES
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Central nervous system trauma induces marked inflammation that has beneficial and deleterious conse-
quences. In a recent issue of Neuron, Gadani et al. (2015) show that injured spinal cord releases the alarmin
IL-33 to drive chemokines that recruit monocytes and promote recovery.It has been long debated whether the
inflammation following central nervous
system (CNS) injury impairs or aids re-
covery. Inflammation is an essential pro-
tective response, killing pathogens andremoving necrotic material, but its
‘‘weapons’’ need to be carefully regulated
to prevent excessive tissue damage. This
is especially the case in the CNS, a tissue
with limited, if any, capacity to regenerate(Norenberg et al., 2004). Much of the
damage seen after injury might not
actually be due to the initial insult but
to secondary inflammation, character-
ized by ischemia, edema, and free-radical2, March 17, 2015 ª2015 Elsevier Inc. 403
Immunity
Previewsformation (Norenberg et al., 2004).
Macrophages, the myeloid lineage innate
immune cells that monitor tissue homeo-
stasis, play an important role both in
injury and repair (David and Kroner,
2011). They are highly plastic and exist
along a continuum of activation states,
with M1 ‘‘proinflammatory’’ polarization
at one end, and M2 ‘‘anti-inflammatory’’
polarization at the other. Both microglia
(CNS-resident macrophage-like cells)
and circulation-derived macrophages are
activated and recruited during CNS injury
to undergoM1orM2differentiation (Miron
and Franklin, 2014). M1 macrophages
contribute to secondary injury by produc-
ing reactive oxygen and nitrogen species
and proteases, leading to lipid peroxida-
tion and membrane damage, followed by
cell death and axon growth inhibition
such that ablatingmacrophages improves
recovery (David and Kroner, 2011). In
contrast, M2 macrophages can promote
recovery by secreting growth factors,
cleaning up debris by phagocytosis, and
encouraging neural stem cell differentia-
tion; ablating these macrophages might
impair recovery (Shechter et al., 2009).
However, this is not a simple yin-yang sit-
uation: both M1 and M2 types contribute
to remyelination, M1macrophages recruit
oligodendrocyte precursors while M2
types encourage their differentiation
(Miron and Franklin, 2014). Because M1
cells can switch to M2 cells, both types
might play a role in recovery and the bal-
ance between damage and repair is com-
plex and dynamic. An open question is
what signals control the recruitment and
skewing of monocytes to a M2 phenotype
after injury and whether this is beneficial.
One candidate is interleukin-33 (IL-33), a
member of the IL-1 superfamily implicated
in amplifying type 2 immune responses
and shifting macrophage polarization to-
ward M2 (Han et al., 2011). IL-33 is
released from damaged cells and serves
as an ‘‘alarmin,’’ an endogenous signal of
tissue injury. To signal, the extracellular
IL-33 binds to its receptor consisting of a
heterodimer between ST2 and IL-1 recep-
tor accessory protein (IL-1RAcP). In addi-
tion, IL-33 is localized in the cell nucleus
where it binds to DNA to modulate NF-
kB-mediated gene expression and in this
way, dampens inflammation. Although
IL-33 has been found to be expressed in
astrocytes, its role in CNS injury is poorly
characterized.404 Immunity 42, March 17, 2015 ª2015 ElseIn the report in Neuron (Gadani et al.,
2015), IL-33 was surprisingly found to be
highly expressed in white matter in the
CNS where it colocalized with oligoden-
drocyte markers, as well as with astrocyte
markers in gray matter. Indeed, flow-cy-
tometry analysis showed that 33% of
naive mouse brain cells expressed IL-33.
After spinal cord contusion, IL-33 levels
transiently increased in the cerebrospinal
fluid 1 hr post injury, but then greatly
decreased at the lesion site. Damage to
the spinal cord in an ex vivo model re-
vealed elevated IL-33 release without
change in transcript expression, suggest-
ing IL-33 pools readily available for quick
release upon tissue insult. Because IL-
33-deficient mice showed significantly
decreased retinal ganglion cell survival
3 days following an optic nerve crush, as
well as some impaired recovery of motor
function after spinal cord contusion, the
authors conclude that IL-33 plays an
adaptive role in CNS repair responses.
Given the role of IL-33 in polarizing mac-
rophages toward an M2 phenotype (Kur-
owska-Stolarska et al., 2009), the authors
next asked whether this was the case af-
ter spinal cord injury. Spinal cord from
IL-33-deficient injured mice showed
decreased M2 marker transcript levels
(Arg1, Mrc, IL10, Chi3l3) whereas bone-
marrow-derived macrophages exposed
to ex vivo lesioned spinal cord along
with IL-4 showed increased Arg1 expres-
sion, implying they were skewed toward
M2. This effect was reduced by an ST2
(IL-33 receptor)-blocking antibody and
abolished in ST2-deficient derived mac-
rophages, suggesting that macrophage
polarization was directly regulated by IL-
33. In the lesioned IL-33-deficient mice,
M2 polarized macrophages were still pre-
sent, indicating that other factors can
polarize and/or recruit these cells. In addi-
tion to directly polarizing macrophages,
IL-33 can also act on upstream targets.
Expression profiling was performed to
identify resident CNS cell types that are
targets of IL-33. Previous reports suggest
that microglia express high levels of St2 in
the naive state (Han et al., 2011). In the
Gadani et al. study spinal cord microglia
showed a decrease in St2 mRNA expres-
sion after injury, whereas astrocytes
increased St2 transcript levels, implying
that in the injured state, astrocytes and
not microglia might be the primary target
for IL-33. The authors also found thatvier Inc.mixed glial cultures exposed to IL-33
release several chemokines and cyto-
kines including CCL5, CXCL1, CXCL10,
CXCL2, and CCL2, whereas IL-33-
deficient mice injured spinal cord had
decreased Ccl2, Cxcl10, and Cxcl2 tran-
scripts. The authors conclude that IL-33
induces astrocytes to release monocyte-
recruiting chemokines. To mimic an IL-
33-induced astrocyte release of CCL2,
the authors administered CCL2 to mice
after spinal cord injury, and this produced
some motor function improvement after
the injury that correlated with elevated
monocyte recruitment (ly6Chi), consistent
with previous findings (Shechter et al.,
2009). However, it is unclear whether
these monocytes are recruited already
polarized or undergo a switch in polariza-
tion at the site of injury.
Another study published earlier this
month by Pomeshchik et al. supports
aspects of Gadani’s findings by showing
that treating mice after spinal cord injury
with exogenous recombinant IL-33 in-
duces M2 polarization and a long-lasting
increased recovery (dayR42 post-injury)
(Pomeshchik et al., 2015). They found
that IL-33 administration led to a Th2-
skewed cytokine profile in the periphery
and production of IL-10. Taken together,
these two reports support the possibility
that an inflammation-mediated release of
IL-33 in response to CNS trauma might
initiate a protective feedback loop
involving T cells, glial cells, and mono-
cytes that somehow acts on neurons.
This complex protective immune
response appears to involve the chemo-
taxis of monocytes by an IL-33-mediated
release of CCL2 from astrocytes, M2 po-
larization following IL-10 release, and an
action of IL-33 on ST2 expressing macro-
phages (Figure 1).
Several major questions remain, and
the model needs clarification. For in-
stance, Gadani et al. suggest that IL-
33 is released by oligodendrocytes
upon injury, in contrast with Pomeshchik
et al. who propose that it comes from
astrocytes. Gain-of-function experiments
evaluating the consequences of oligoden-
drocyte activation on M2 polarization and
recovery from CNS injury are needed. The
mechanism by which IL-33 is released,
and if oligodendrocyte death is neces-
sary, also remains unclear. Gadani et al.
suggest that astrocytes via ST2 are the
main target of the injury-released IL-33,
Figure 1. Oligodendrocytes Sound the Alarm upon CNS Injury
In a model based on Gadani et al., spinal cord contusion injury promotes IL-33 release from oligodendro-
cytes. Other as-yet-to-be identified factors are also released and increase astrocyte expression of St2
(IL-33R) and decrease its expression in microglia. Newly released IL-33 stimulates astrocytes to promote
monocyte chemotaxis through the CCL2-CCR2 axis. Diverse factors, including IL-33, skew these invading
macrophages to adopt a M2 polarized state that then promotes injury recovery.
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monocytes. However, microglia, T cells,
macrophages, and neurons all express
ST2 and could contribute to the alarmin’s
actions. Certainly, microglia have been
found to recruit circulatory monocytes to
the CNS in some circumstances (David
and Kroner, 2011).
Administration of recombinant IL-33
can attenuate experimental autoimmune
encephalomyelitis in mice by suppressingIL-17 and interferon-g (IFN-g) production
and by inducing alternatively activated
macrophages (Jiang et al., 2012). Such
administration might be beneficial for
treating the following: brain trauma, if
M2 macrophages mitigate the extent of
damage; stroke, where a lack of M2-
derived IL-4 and IL-10 increases infarct
volume and worsens cognitive perfor-
mance; and multiple sclerosis, where
M2 macrophages drive oligodendrocyteImmunity 4differentiation during CNS remyelination
(Miron and Franklin, 2014). However, M2
macrophages promote tumor progres-
sion in primary CNS lymphoma (Komo-
hara et al., 2011), and manipulating
macrophage polarization would need to
be done carefully in the right context, al-
ways ensuring that such intervention
does no harm. In addition, it should be
kept in mind that although classifying
macrophages into M1 and M2 is useful,
it is artificial, because macrophages in
a particular environment might have
characteristics of both polarization states
and switch from one to the other. Never-
theless, the findings of Gadani et al.
open a new neuro-immunology perspec-
tive—one where alarmins are released
after injury to recruit and polarize macro-
phages toward an M2 phenotype, pro-
tecting neurons from further damage—
potentially providing new therapeutic
targets for CNS injury.
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